Cargando…
Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
Currently, there is a paucity of evidence to guide the management of antipsychotic therapy at the end of life for patients with schizophrenia. A 51-year-old female with a diagnosis of palliative squamous cell carcinoma of the tonsils was admitted to her local hospice for end-of-life care. She had a...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241334/ https://www.ncbi.nlm.nih.gov/pubmed/34223460 http://dx.doi.org/10.1089/pmr.2020.0039 |